Chronic myeloid leukaemia (CML) is a myeloproliferative disorder promoted by the
constitutive tyrosine kinase activity of Bcr-Abl oncoprotein. Although treatment with the Bcr …

Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr-Abl, a constitutively
active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype …

Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends
on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML …

Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the
BCR-ABL oncogene. Despite the high performance of treatment with tyrosine kinase …

Imatinib and other selective inhibitors of BCR-ABL are the mainstay of chronic myelogenous
leukemia (CML) treatment, but resistance to these drugs limits their efficacy. Known …

Patients with chronic myeloid leukemia (CML) who are treated with tyrosine kinase inhibitors
(TKIs) experience significant heterogeneity regarding depth and speed of responses …

As tyrosine kinase inhibitors (eg, Imatinib, IM) fail to induce long-term response in some
chronic myeloid leukemia (CML), novel therapies targeting leukemia-dysregulated pathways …

Resistance to the BCR-ABL inhibitor imatinib mesylate (IM) poses a major problem for the
treatment of chronic myeloid leukemia (CML). IM resistance often results from a secondary …

Chronic myelogenous leukemia (CML) is triggered by the constitutively activated BCR-ABL
oncoprotein and multiple downstream signaling pathways, including the Raf/MEK/ERK …

In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway
is crucial for survival and proliferation of leukemic cells. Essential downstream molecules …